Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NTRB 
Nutriband Inc (NTRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: NTRB (1-star) is a SELL. SELL since 1 days. Simulated Profits (-4.63%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.8% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.11M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 1 | Beta 1.14 | 52 Weeks Range 3.72 - 11.78 | Updated Date 10/23/2025 |
52 Weeks Range 3.72 - 11.78 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-01 | When - | Estimate -0.17 | Actual -2.12 |
Profitability
Profit Margin - | Operating Margin (TTM) -321.83% |
Management Effectiveness
Return on Assets (TTM) -35.74% | Return on Equity (TTM) -98% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 81475571 | Price to Sales(TTM) 32.63 |
Enterprise Value 81475571 | Price to Sales(TTM) 32.63 | ||
Enterprise Value to Revenue 31.6 | Enterprise Value to EBITDA -4.55 | Shares Outstanding 12015983 | Shares Floating 3982818 |
Shares Outstanding 12015983 | Shares Floating 3982818 | ||
Percent Insiders 70.78 | Percent Institutions 2.89 |
Upturn AI SWOT
Nutriband Inc
Company Overview
History and Background
Nutriband Inc., formerly known as Nutranomics, Inc., focuses on pharmaceutical transdermal technology. Founded to develop and commercialize abuse-deterrent transdermal products, particularly the AVERSAu2122 abuse-deterrent transdermal technology.
Core Business Areas
- AVERSAu2122 Technology: The development and commercialization of the AVERSAu2122 abuse-deterrent transdermal technology, designed to prevent opioid abuse and misuse.
- Transdermal Products: Developing a portfolio of transdermal products leveraging their technology for various therapeutic applications.
- Nutriband Patch: Developing and marketing a childrenu2019s vitamin patch.
Leadership and Structure
Details about the leadership team, including names and positions, and the overall organizational structure are not publicly available.
Top Products and Market Share
Key Offerings
- AVERSAu2122 Technology: Abuse-deterrent transdermal technology for opioid medications. Market share is speculative as it is not yet commercialized. Competitors include companies developing abuse-deterrent formulations such as Collegium Pharmaceutical (COLL) and Teva Pharmaceutical (TEVA).
- Nutriband Patch: A vitamin patch for children. Market share and revenue are not publicly available. Competitors include companies offering vitamin supplements for children.
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive and highly regulated, with increasing focus on abuse-deterrent formulations and alternative drug delivery methods like transdermal patches. The vitamin supplement market is also competitive.
Positioning
Nutriband aims to differentiate itself with AVERSAu2122 technology in the abuse-deterrent opioid market. Competes with established players in generic pharmaceuticals and drug delivery systems.
Total Addressable Market (TAM)
The opioid abuse-deterrent market is estimated at billions of dollars. The children's vitamin patch market is a smaller segment but still substantial. Nutriband is positioned to capture a portion of the abuse-deterrent market if AVERSAu2122 is successfully commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary AVERSAu2122 technology
- Potential for abuse-deterrent opioid products
- Transdermal drug delivery expertise
Weaknesses
- Limited revenue and profitability
- Reliance on successful commercialization of AVERSAu2122
- Small market capitalization
- High dependence on financing
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into other transdermal applications
- Government initiatives supporting abuse-deterrent formulations
Threats
- Regulatory hurdles and approval processes
- Competition from larger pharmaceutical companies
- Patent challenges to AVERSAu2122 technology
- Changes in opioid prescribing practices
Competitors and Market Share
Key Competitors
- COLL
- TEVA
- ENDP
Competitive Landscape
Nutriband faces significant competition from established pharmaceutical companies with greater resources and market access. Its success hinges on the differentiated value proposition of AVERSAu2122 and its ability to secure partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to lack of commercialized products.
Future Projections: Future growth depends on the successful commercialization of AVERSAu2122 technology and partnerships. Analyst estimates are not available.
Recent Initiatives: Recent initiatives include patent applications and collaborations for AVERSAu2122 technology and development of other transdermal products.
Summary
Nutriband Inc. is a development-stage company focused on transdermal drug delivery. The company's strength lies in its proprietary AVERSAu2122 technology and its potential to address the opioid abuse crisis. However, the company faces significant challenges, including the need for regulatory approval and competition from larger pharmaceutical companies. Its success depends on securing partnerships and successfully commercializing its technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2017-11-30 | Founder, Acting CEO, President, Company Secretary & Executive Chairman of the Board Mr. Serguei Melnik | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.